- NCGM inaugurates NOVASEQ 6000
- Neuberg inks its intention to collaborate with CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB) for licensing of technologies / know-how for various genomics-scale biomedical applications.
Neuberg Diagnostics Private Limited (NDPL), ranking among the top 4 diagnostic service providers in the country, today launched Neuberg Center for Genomic Medicine (NCGM). Dr. Anurag Agrawal, Director, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) and Head of Translational Research in Lung Diseases, inaugurated the Center and informed about CSIR-IGIB’s in principal agreement to partner with NDPL for licensing of technologies for various genomics-scale healthcare applications including population-scale whole genome sequencing, knowledgebase for which has been developed at CSIR-IGIB.
The Neuberg Center for Genomic Medicines strengths encompass comprehensive Genomics Core facility allowing for large-scale clinical and research projects including whole exome sequencing, whole genome sequencing, proteomics, high content screening and cytogenetics. Moreover, NCGM is extremely unique in its organizational structure consisting of a dedicated team of translational scientists trained with both Medical (MD) and/or research (PhD) training, heading each unit such as Immunogenetics, Solid Oncology, Hemato-oncology, Reproductive Medicine, Infectious Diseases, Inherited Genomics as well as Bioinformatics.
NCGM today also inaugurated the NOVASEQ 6000, the highest throughput DNA sequencer currently available in the world. With its acquisition, NCGM is the only private lab in country to house the most powerful sequencer which offers high-throughput sequencing across a broad range of applications. It supports the study of genetic links between health and disease at an unprecedented scale by making it possible to sequence more samples at greater depth, in order to discover rare and novel genetic variants. This advanced sequencing system will make it possible to envision a future in which all people can benefit from Precision Medicine.
Dr. Sandip Shah, Executive Director, Neuberg Diagnostics Private Limited, commented at the launch, “NovaSeq 6000 will help researchers access next-generation sequencing technology and more easily conduct large-scale genomics projects with greater sample volumes at an unprecedented depth and coverage of the genome.”
Commenting during the launch, Dr. G. S. K. Velu, Chairman & Managing Director, Neuberg Diagnostics Private Limited said “Neuberg’s focus and aim have always been technological advancement in medicine. The launch of NovaSeq is a proud moment for us as not only are we bringing the best technology to India but we are also the only private company to bring this technology. Being the most advanced and powerful sequencer, NovaSeq will enable us to attain a deeper understanding of the human genome as we strive to uncover causes and treatments for various complex disorders”
Neuberg intents to collaborate with CSIR-IGIB, the premier laboratory of CSIR, having demonstrated expertise in Genomics with aim to utilize India’s intrinsic sequencing capacity and showcase the tremendous advantage of employing local technical resources and manpower across India’s public and private sector as we work to fulfil the mission of ‘Make in India’.
Dr. Anurag Agrawal, Director, CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB) said, “Health ecosystems of future will be based on the idea of digital twins, our digital health equivalents, monitored and evaluated by wellness algorithms. Genomics is at the core of these concepts and I am delighted to see that the Indian private sector is now working in concert with academic organizations for creating next-generation services of social and economic importance to India.”